Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is considered one of the best fundamentally strong penny stocks to buy by analysts. ARK Investment acquired over 755,000 shares of RXRX in a $3.35 million transaction. JPMorgan upgraded RXRX from Neutral to Overweight with a price target of $11.00, citing promising results from the MEK 1/2 inhibitor REC-4881. The company’s AI-driven pipeline, including REC-617, has potential for peak sales exceeding $1 billion. With a ‘Hold’ rating from 63% of analysts and a median price target of $7, RXRX has an upside potential of 64.32%. Founded in 2013, RXRX focuses on decoding biology and chemistry with products like REC-994 and REC-2282.

Read more at Yahoo Finance: Is Recursion Pharmaceuticals, Inc. (RXRX) the Best Fundamentally Strong Penny Stock to Buy?